SCOPE 2023: Challenging Operational Aspects of Clinical Trials

Article

Len Rosenberg, head of clinical operations at Beat AML, reveals how changing the backbone treatment to a different regimen is beneficial to the patient, in terms of the safety with the same efficacy.

In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Len Rosenberg, head of clinical operations at Beat AML, explains the operational obstacles that come with clinical trials, including background treatment dosages.

Related Videos
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.